Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.

Relmada Therapeutics, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

POSTER HIGHLIGHTS 6-MONTH FOLLOW-UP DATA FROM THE ONGOING PHASE 2 TRIAL OF NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC), WITH FAVORABLE OVERALL SAFETY RELMADA PLANS TO ADVANCE NDV-01, A SUSTAINED RELEASE INTRAVESICAL FORMULATION OF GEMCITABINE/DOCETAXEL (GEM/DOCE), INTO PHASE 3 STUDIES IN TWO INDICATIONS IN H1 2026 COMPANY IS FOCUSED ON HIGH-RISK NMIBC AND INTERMEDIATE-RISK NMIBC, REPRESENTING ABOUT 80% OF NEW NMIBC CASES EVERY YEAR, OR ABOUT 54,000 PEOPLE IN THE UNITED STATES CORAL GABLES, FLA., DEC. 03, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED THAT THE PREVIOUSLY DISCLOSED 6-MONTH FOLLOW-UP DATA FROM THE ONGOING PHASE 2 STUDY OF NDV-01, A SUSTAINED RELEASE, INTRAVESICAL FORMULATION OF GEMCITABINE AND DOCETAXEL (GEM/DOCE), IN DEVELOPMENT FOR NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC) WILL BE PRESENTED IN A POSTER AT THE SOCIETY OF UROLOGIC ONCOLOGY 26TH ANNUAL MEETING (SUO 2025).

RELMADA THERAPEUTICS ANNOUNCES PRESENTATION OF NDV-01 PHASE 2 DATA AT THE SOCIETY FOR UROLOGIC ONCOLOGY

POSITIVE 9-MONTH FOLLOW-UP DATA FOR NDV-01 SHOWED A 92% OVERALL RESPONSE RATE AT ANY TIME IN NON-MUSCLE INVASIVE BLADDER CANCER (NMIBC), WITH FAVORABLE OVERALL SAFETY

RELMADA THERAPEUTICS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES KEY CLINICAL, REGULATORY, AND CORPORATE UPDATES

CORAL GABLES, FLA., NOV. 07, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, NOVEMBER 13, 2025 AT 4:30 PM ET TO DISCUSS FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025 AND RECENT BUSINESS PROGRESS.

RELMADA THERAPEUTICS TO REPORT THIRD QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, NOVEMBER 13, 2025

CORAL GABLES, FLA., NOV. 04, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED THE PRICING OF ITS UNDERWRITTEN OFFERING OF 40,142,000 SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE UP TO 5,315,000 SHARES OF COMMON STOCK.

RELMADA THERAPEUTICS ANNOUNCES PRICING OF $100 MILLION UNDERWRITTEN OFFERING OF COMMON STOCK AND PRE-FUNDED WARRANTS

ANNOUNCES NDV-01 9-MONTH FOLLOW-UP SAFETY AND EFFICACY DATA IN NMIBC FDA FEEDBACK SUPPORTS 2 POTENTIAL REGISTRATIONAL TRIALS  1) A REGISTRATIONAL TRIAL IN 2ND LINE REFRACTORY BCG-UNRESPONSIVE NMIBC, AND 2) A RANDOMIZED CONTROLLED TRIAL IN INTERMEDIATE-RISK NMIBC. FDA FEEDBACK ALSO CONFIRMS NO ADDITIONAL NON-CLINICAL STUDIES ARE REQUIRED.

RELMADA ANNOUNCES FDA FEEDBACK SUPPORTING 2 SEPARATE ACCEPTABLE REGISTRATIONAL STUDY PATHS FOR NDV-01 IN NON-MUSCLE INVASIVE BLADDER CANCER

DR. KATES' EXPERIENCE AS CHAIR OF THE LANDMARK PHASE 3 BRIDGE BLADDER CANCER TRIAL AND DEDICATION TO PATIENT CARE WILL BE INVALUABLE TO THE NDV-01 PHASE 3 PROGRAM

RELMADA THERAPEUTICS APPOINTS DISTINGUISHED UROLOGIC ONCOLOGIST, MAX KATES, MD, TO THE CLINICAL ADVISORY BOARD TO SUPPORT DEVELOPMENT OF NDV-01

CORAL GABLES, FLA., SEPT. 16, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY-RELATED AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED THAT ON SEPTEMBER 15, 2025 IT RECEIVED WRITTEN NOTICE FROM THE NASDAQ STOCK MARKET LLC (NASDAQ) CONFIRMING THAT THE COMPANY HAS REGAINED COMPLIANCE WITH NASDAQ'S $1.00 MINIMUM BID PRICE REQUIREMENT UNDER NASDAQ LISTING RULE 5550 (A)(2) (THE LISTING RULE).

RELMADA REGAINS COMPLIANCE WITH NASDAQ MINIMUM BID PRICE REQUIREMENT

CORAL GABLES, FLA., SEPT. 10, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY-RELATED AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ISSUED A LETTER TO SHAREHOLDERS FROM SERGIO TRAVERSA, CHIEF EXECUTIVE OFFICER.

RELMADA ISSUES MID-YEAR CEO LETTER TO SHAREHOLDERS

CORAL GABLES, FLA., JULY 31, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED PLANS TO HOST A CONFERENCE CALL AND WEBCAST ON THURSDAY, AUGUST 7, 2025 AT 4:30 PM ET TO DISCUSS FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025 AND RECENT BUSINESS PROGRESS.

RELMADA THERAPEUTICS TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS ON THURSDAY, AUGUST 7, 2025

DR. LOTAN'S DISTINGUISHED EXPERTISE IN BLADDER CANCER CARE AND CLINICAL DEVELOPMENT BRINGS FURTHER SCIENTIFIC ACUMEN TO RELMADA'S NDV-01 PROGRAM PHASE 3 TRIAL FOR NDV-01 EXPECTED TO BEGIN IN H1 2026 CORAL GABLES, FLA., JULY 15, 2025 (GLOBE NEWSWIRE) -- RELMADA THERAPEUTICS, INC. (NASDAQ: RLMD, RELMADA OR THE COMPANY), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY ADVANCING INNOVATIVE THERAPIES FOR ONCOLOGY AND CENTRAL NERVOUS SYSTEM INDICATIONS, TODAY ANNOUNCED THE APPOINTMENT OF YAIR LOTAN, MD, A DISTINGUISHED UROLOGIC ONCOLOGIST, AS CHAIR OF RELMADA'S CLINICAL ADVISORY BOARD (CAB).

Relmada Therapeutics, Inc.

RLMD

Price

Financial Reports

No items found.

Press Releases

Relmada Therapeutics, Inc.

RLMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

RLMD